Annals of Oncology Advance Access originally published online on June 18, 2008
Annals of Oncology 2008 19(8):1510-1511; doi:10.1093/annonc/mdn397
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
letters to the editors |
Large bowel perforation associated with capecitabine treatment for breast cancer
| The first 10% of the full text of this article appears below. |
Capecitabine is an oral fluorouracil prodrug which is licenced for treatment of metastatic breast and colorectal cancer [1, 2]. Toxic effects are similar to fluorouracil and include diarrhoea and hand–foot syndrome which resolve on drug withdrawal. We report two cases of large bowel perforation associated with
Department of Medical Oncology, Charing Cross Hospital, Fulham Palace Road, London, UK
* (E-mail: marktuthill@doctors.org.uk)